SCHEMBL2918265

SCHEMBL2918265

CCOC(=O)N1CC=CCN1C(=O)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
HTR2C P28335 1/20 0.50
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
PSEN1 P49768 1/20 0.48
PSEN2 P49810 1/20 0.48
APH1B Q8WW43 1/20 0.48
NCSTN Q92542 1/20 0.48
APH1A Q96BI3 1/20 0.48
PSENEN Q9NZ42 1/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
L3MBTL1 Q9Y468 3/20 0.47
P2RX4 Q99571 2/20 0.47
CYP2C19 P33261 2/20 0.46
P2RX1 P51575 1/20 0.46
P2RX3 P56373 1/20 0.46
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2914776 0.94 KMT2A (0.54) ALDH1A1HTR2CKMT2AMEN1NPSR1
SCHEMBL2914778 0.89 KMT2A (0.50) ALDH1A1HTR2CKMT2AMEN1NPSR1
SCHEMBL7658562 0.81 L3MBTL1 (0.68) ALDH1A1KMT2AMEN1NPSR1NPC1
SCHEMBL92054 0.80 KMT2A (0.62) ALDH1A1HTR2CKMT2AMEN1NPSR1
SCHEMBL16612115 0.80 KMT2A (0.58) ALDH1A1HTR2CKMT2AMEN1NPSR1
SCHEMBL4740593 0.79 NPC1 (0.43) ALDH1A1HTR2CKMT2AMEN1NPSR1
SCHEMBL3880611 0.78 NPC1 (0.45) HTR2CKMT2AMEN1NPSR1NPC1
SCHEMBL9358292 0.77 ALDH1A1 (0.53) ALDH1A1HTR2CKMT2AMEN1NPSR1
SCHEMBL9354941 0.77 ALDH1A1 (0.53) ALDH1A1HTR2CKMT2AMEN1NPSR1
SCHEMBL7279646 0.76 KMT2A (0.54) ALDH1A1HTR2CKMT2AMEN1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-20060189591-A1 Five-membered heterocyclic derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 US disclosed
EP-1621537-A1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-01 EP disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 ALDH1A1 139/4885HTR2C 441/4885KMT2A 4370/4885
US-20060189591-A1 Five-membered heterocyclic derivative PTGS1, PTGIS, PTGS2 ALDH1A1 251/4885HTR2C 566/4885KMT2A 4143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.